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Abstract
Background: Various abnormalities of haemostasis have been described in patients with hyperthyroidism. The results of different studies 
point to the underlying thyroid disease, especially severity of hyperthyroidism and autoimmune processes, as important factors contribut-
ing to coagulation-fibrinolytic balance. The objective of this study was to investigate the association between hyperthyroidism (concerning 
severity of thyroid dysfunction and anti-thyroid perioxidase antibodies level) and plasma fibrinogen and D-dimers levels before and after 
radioiodine therapy.
Material and methods: The study included 35 non-smoking, postmenopausal women, aged 51–69, with subclinical or overt hyperthyroidism 
treated with radioiodine. Analysis comprised serum TSH (thyroid stimulating hormone), fT4 (free thyroxine), fT3 (free triiodothyronine), 
TPO antibodies (anti-thyroid perioxidase) levels, and plasma D-dimers and fibrinogen levels before and 12-16 weeks and 24–28 weeks 
after radioiodine therapy.
Results: Elevated fibrinogen (3.82 g/L ± 0.75, reference range 2–4.5 g/L) and D-dimers (674.26 ng/mL ± 652.71, reference range 70–490 
ng/mL) levels were observed in subjects with hyperthyroidism. They decreased after radioiodine therapy. A negative correlation between 
plasma fibrinogen and D-dimers levels and anti-thyroid perioxidase antibodies level was found. TSH, fT4 and fT3 correlated with D-dimers 
level in overt hyperthyroidism.
Conclusions: Hyperthyroidism is associated with a tendency toward hypercoagulation and hyperfibrinolysis. The changes observed in 
plasma fibrinogen and D-dimers levels are reversible. Fibrinogen level decreases within reference range and D-dimers level decreases 
almost to the upper reference range. They depend on severity and autoimmunity of the underlying thyroid disease and may be modified 
by restoring euthyroidism. (Pol J Endocrinol 2011; 62 (5): 409–415)
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Streszczenie
Wstęp: U pacjentów z nadczynnością tarczycy opisano różne zaburzenia hemostazy. Wyniki publikowanych dotychczas prac sugerują, że 
najważniejszymi czynnikami, od których zależy równowaga procesów koagulacji i fibrynolizy, są stopień nasilenia choroby tarczycy oraz 
procesy autoimmunologiczne. Celem prezentowanej pracy jest ocena stężeń fibrynogenu i D-dimerów w nadczynności tarczycy przed 
leczeniem i po podaniu 131I w zależności od nasilenia choroby i braku lub obecności przeciwciał przeciw tyreoperoksydazie.
Materiał i metody: Do badania włączono 35 niepalących kobiet po menopauzie, w wieku 51–69 lat, z subkliniczną lub jawną klinicznie 
nadczynnością tarczycy, leczonych 131I. Badano stężenia tyreotropiny (TSH), wolnej tyroksyny (fT4), wolnej trójjodotyroniny (fT3), przeciwciał 
przeciw tyreoperoksydazie (anty-TPO) oraz fibrynogenu i D-dimerów przed leczeniem oraz 12–16 tygodni i 24–28 tygodni po podaniu 131I.
Wyniki: U kobiet z nadczynnością tarczycy obserwowano podwyższone stężenie fibrynogenu (3,82 g/L ± 0,75, norma 2–4,5 g/L) i D-dimerów 
(674,26 ng/mL ± 652,71, norma 70–490 ng/mL), które obniżały się po leczeniu 131I. Stwierdzono ujemną korelację pomiędzy stężeniem 
fibrynogenu i D-dimerów a stężeniem przeciwciał anty-TPO. U pacjentek z jawną klinicznie nadczynnością tarczycy uzyskano dodatnią 
korelację pomiędzy stężeniem TSH, fT4, fT3 a stężeniem D-dimerów.
Wnioski: Nadczynność tarczycy wiąże się z większą skłonnością do koagulacji i fibrynolizy. Stężenie fibrynogenu zmniejsza się w zakre-
sie wartości referencyjnych, natomiast D-dimerów zmniejszając się, osiąga górny zakres wartości referencyjnych. Zmiany obserwowane 
w stężeniu fibrynogenu i D-dimerów są odwracalne. Zależą od stopnia nasilenia nadczynności tarczycy oraz procesów autoimmunolo-
gicznych, a także podlegają modyfikacji po przywróceniu prawidłowej funkcji tarczycy.
(Endokrynol Pol 2011; 62 (5): 409–415)
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Introduction
Thyroid dysfunction may cause mild changes in pri-
mary and secondary haemostasis or lead to clinically 
important thrombosis or haemorrhage. It has been 
suggested that hyperthyroidism is associated with 
hypercoagulability and hypofibrinolysis but there is as 
yet little data on subclinical hyperthyroidism [1]. The 
direct and indirect effects of excessive thyroid hormones 
on thrombocytes, coagulation factors and blood viscos-
ity are responsible for disturbances in coagulation and 
fibrinolytic system [1]. Some authors suggest thyroid- 
-related autoimmune processes may be involved [2–4] 
while others argue that the haemostatic balance is rarely 
affected by such mechanisms [5].
Thrombocytopenia in hyperthyroidism is consid-
ered to be a metabolic consequence of thyroid hor-
mone elevation [6] (i.e. thyrotoxicosis may increase the 
phagocytic activity of the reticuloendothelial system) 
[7, 8]. However, the relationship between autoimmune 
thrombocytopenic purpura and hyperthyroidism has 
also been described [9, 10].
Hypercoagulability results from the following 
biological mechanisms [2, 11–13]: an increased hepatic 
protein synthesis [14], an increased acute phase re-
actants synthesis [14–16], an excessive production of 
tissue factor [17], an increased thrombin and plasmin 
activity [14] and an increased level of the indicators 
of endothelial damage (i.e. thrombomodulin and von 
Willebrand factor) [13–15, 18].
An excess fluid loss (due to an increased metabolism) 
and an increase in blood volume (due to an increase 
in red blood cell level) also contribute to hypercoagu-
lability.
Thyroid hormones exert effect on haemostasis 
through nuclear receptor by altering gene expression 
of many proteins originating from the liver and endo-
thelium [15, 19, 20].
Hyperthyroidism, overt and subclinical, alters the 
coagulation-fibrinolytic balance. Various changes have 
been described in patients with hyperthyroidism [5]. 
Several reports have demonstrated high plasma
fibrinogen level in hyperthyroid states [13, 14, 21, 
22]. The relation of subclinical hyperthyroidism to the 
blood coagulation system has not been extensively 
studied. It is suggested that these abnormalities are 
independent of the underlying pathophysiology of 
thyroid disease [5]. Changes are reported to return to 
normal after treatment. Hyperthyroidism is associated 
with higher thromboembolic potential [13, 22]. Another 
study confirmed the hypercoagulable state in subclinical 
hyperthyroidism [20]. 
The purpose of this study is to evaluate the as-
sociation between type of hyperthyroidism (degree 
of thyroid dysfunction and thyroid autoimmunity), 
haemostatic parameters (fibrinogen and D-dimers) and 
radioiodine therapy.
Material and methods
35 non-smoking, postmenopausal women aged 
51–69 were involved. The mean age was 59 years. We 
chose postmenopausal and non-smoking women in 
order to include a homogenous group of patients 
and to exclude the influence of smoking and effect 
of oestrogen on coagulation–fibrinolytic balance. All 
patients were hyperthyroid (21 with toxic goitre, six 
with autonomous functioning thyroid nodule, seven 
with Graves’ disease, and one with toxic goitre and 
Graves’ disease). They were divided into subgroups 
according to severity of disease. 20 of them pre-
sented with subclinical hyperthyroidism (defined 
as TSH < 0.4 uIU/mL and fT4 < 20 pmol/L) and 
15 presented with overt hyperthyroidism (defined 
as TSH < 0.4 uIU/mL and fT4 > 20 pmol/L). Patients 
were also divided into two categories according to 
level of anti-thyroid peroxidase antibodies. Anti-TPO 
antibodies refer to undergoing autoimmune process-
es. As there is very little data on the type of antibod-
ies and their usefulness in investigating haemostasis 
balance in thyroid dysfunction [8], we chose these 
antibodies because they are commonly measured in 
clinical practice: 27 patients had antibodies within the 
norm (< 35 IU/mL) and in eight the level of antibod-
ies was elevated (> 35 IU/mL). None of the patients 
had a history of concomitant disease that could have 
influenced the coagulation-fibrinolytic balance. The 
study protocol was approved by the Ethics Committee 
for Human Studies of Wroclaw Medical University. 
Informed written consent was obtained from all 
subjects after explanation of the nature, purpose and 
potential risk of the study.
In all patients, levels of TSH, fT4, fT3, TPO antibod-
ies, fibrinogen and D-dimers were measured using 
commercial methods (Siemens Immulite 2000 Systems 
TSH 3rd Generation, Siemens Immulite 2000 Systems 
ST4, Siemens Immulite 2000 Systems ST3, Siemens 2000 
Systems ATA for TPO antibodies, Siemens Multifibrin 
for fibrinogen and Biomerie Ups. Vidas D-dimer exclu-
sion). The measurements were taken three times: once 
before administration of radioiodine, once between 
12 and 16 weeks after radioiodine therapy, and 
again between 24 and 28 weeks after radioiodine 
therapy. Reference ranges were 0.4–4 uIU/mL for 
TSH, 9–20 pmol/L for fT4, 4–8.3 pmol/L for fT3 and 
0–35 IU/mL for TPO antibodies. Reference ranges for 
haemostatic parameters were 2–4.5 g/L for fibrinogen 
and 70–490 ng/mL for D-dimers.
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Results are expressed as mean ± standard deviation. 
Statistical comparisons for study group before and after 
treatment were made by Student’s t-test. Differences 
were considered statistically significant when p < 0.05 
was obtained.
Results 
The mean plasma fibrinogen and D-dimers levels in 
hyperthyroid women are shown in Figures 1 and 2.
Analysis revealed no association between TSH, fT4 
and fT3 and fibrinogen and D-dimers. Plasma fibrino-
gen level measured 12 -16 weeks after treatment was 
inversely correlated with TPO antibodies levels mea-
sured at the same time (r = –0.19, p < 0.001).
Plasma D-dimers level measured 24-28 weeks after 
treatment was inversely correlated with antibodies 
level measured at the same time (r = –0.244, p < 0.001).
To determine if the severity of hyperthyroid-
ism influenced the coagulation-fibrinolytic system, 
the 35 hyperthyroid women were divided into two 
groups: subclinical (20) and overt (15) hyperthyroidism. 
The mean plasma fibrinogen and D-dimers levels in 
20 women with subclinical hyperthyroidism are shown 
in Figures 3 and 4.
Analysis revealed no association between TSH, fT4, 
fT3 and fibrinogen and D-dimers.
Plasma fibrinogen level was not associated with TPO 
antibodies level.
Plasma D-dimers level measured 12–16 and 24–28 
weeks after treatment was negatively correlated with 
TPO antibodies level measured at the same time 
(r = –0.19, p < 0.01; r = –0.2, p < 0.01).
The mean plasma fibrinogen and D-dimers levels in 
15 women with overt hyperthyroidism are presented 
in Figures 5 and 6.
Analysis revealed no association between TSH, fT4, 
fT3 and fibrinogen.
D-dimers plasma level before radioiodine therapy 
was inversely correlated with TSH level (r = –0.13, 
p < 0.01), positively correlated with fT4 level (r = 0.4, 
p < 0.01) and did not correlate with fT3 level (r = 0.09, 
Figure 1. Fibrinogen [g/L] in hyperthyroidism
Rycina 1. Fibrynogen [g/L] w nadczynności tarczycy
Figure 2. D-dimers [ng/mL] in hyperthyroidism
Rycina 2. D-dimery [ng/mL] w nadczynności tarczycy
Figure 3. Fibrinogen [g/L] in subclinical hyperthyroidism
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Figure 4. D-dimers [ng/mL] in subclinical hyperthyroidism
Rycina 4. D-dimery [ng/mL] w subklinicznej nadczynności 
tarczycy
Figure 6. D-dimers [ng/mL] in overt hyperthyroidism
Rycina 6. D-dimery [ng/mL] w jawnej klinicznie nadczynności 
tarczycy
Figure 5. Fibrinogen [g/L] in overt hyperthyroidism
Rycina 5. Fibrynogen [g/L] w jawnej klinicznie nadczynności 
tarczycy
Table I. Correlation between fibrinogen and anti-TPO in overt hyperthyroidism
Tabela I. Korelacja pomiędzy fibrynogenem a anty-TPO w jawnej klinicznie nadczynności tarczycy
TPO antibodies 1 TPO antibodies 2 TPO antibodies 3
FIBRINOGEN 1 r = 0.007, p = 0.01 No calculation No calculation
FIBRINOGEN 2 r = –0.29, p = 0.05 r = –0.25, p = 0.001 No calculation
FIBEINOGEN 3 r = –0.02, p = 0.05 No calculation r = 0.29, p = 0.05
p < 0.01). Both plasma fibrinogen and D-dimers levels 
were correlated with TPO antibodies level (Tables I, II).
The difference in plasma fibrinogen and D-dimers 
levels between women with hyperthyroidism, subclini-
cal hyperthyroidism and overt hyperthyroidism was 
statistically non-significant. Analysis revealed no cor-
relation between fibrinogen, D-dimers level and dose 
of radioiodine.
Discussion
The aim of our study was to investigate changes in 
coagulation and fibrinolysis in various types of hyper-
thyroidism. Our data showed plasma fibrinogen level in 
the upper laboratory range in subjects before treatment, 
which was in agreement with previous studies. The 
same results were obtained by Burggraaf et al. [14]. In 
their study on endothelial function in patients with 
hyperthyroidism, they found that fibronectin and fi-
brinogen levels were increased. Erem et al. investigated 
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coagulation and fibrinolysis and proved significantly 
increased fibrinogen in hyperthyroid patients compared 
to euthyroid controls [13]. Lippi et al. found high fibrino-
gen values in outpatients with hyperthyroidism [23]. 
Dörr et al. revealed elevated plasma fibrinogen levels 
in subjects with decreased serum TSH [24]. 
In our study, we observed that fibrinogen level 
decreased after radioiodine therapy. We found no as-
sociation between plasma fibrinogen level and dose 
of radioiodine, which may suggest that this effect 
depends on restoring normal thyroid function rather 
than the dose of radioiodine. Our findings are con-
sistent with Burggraaf et al.’s and Marongiu et al.’s 
observation. In Burggraaf ’s study, fibrinogen level 
returned to normal after treatment with thiamazol 
[14]. Marongiu et al. investigated fibrinogen levels first 
in Graves’ disease and then in hyperthyroid patients 
before and after treatment [15, 16]. It was elevated in 
hyperthyroidism and returned to normal values after 
restoring euthyroidism. 
The severity of thyroid dysfunction may have a sig-
nificant influence on the haemostatic balance. Hypothy-
roidism is generally associated with bleeding tendency 
[5, 25–27]. However, it has been suggested that the risk 
for thrombosis may be increased in subclinical or mod-
erate hypothyroidism, as is the risk for haemorrhage in 
overt hypothyroidism [1, 28, 29]. In hyperthyroidism, 
a tendency toward thrombosis has been observed [1]. 
Some authors have underlined that there is still little 
data available on coagulation and fibrinolysis in sub-
clinical hypothyroidism and hyperthyroidism [2].
To evaluate changes in plasma fibrinogen level ac-
cording to severity of thyroid disease, subjects were 
divided into two groups: subclinical hyperthyroidism 
and overt hyperthyroidism. In both groups, plasma 
fibrinogen levels were elevated. The same conclusions 
were drawn from systematic review of thyroid dys-
function and effects on coagulation and fibrinolysis by 
Squizzato et al. and from a brief report on the association 
between thyrotropin and fibrinogen, in which Dörr et 
al. focused on subclinical hyperthyroidism [5, 24]. 
Our data, obtained for subclinical hyperthyroidism, 
confirmed decreasing plasma fibrinogen after radioio-
dine therapy during the whole observation. In overt 
hyperthyroidism, lower plasma fibrinogen level was 
observed only at first measurement after radioiodine 
therapy. 
We decided to measure fibrinogen and D-dimers 
levels twice after treatment in order to confirm that 
observed changes are not transient. In the study by 
Burgraaf et al., fibrinogen level was measured after one 
week of treatment with propranolol, and after thera-
peutic treatment with thiamazol, when it returned to 
normal [14].We did not find data on repeated D-dimer 
measurements in other authors. In Squizzato et al.’s 
article, fibrinogen and D-dimer levels were measured 
only once after treatment [5].
Our data revealed no association between TSH, fT4, 
fT3 and fibrinogen. This is inconsistent with Debeij et 
al.’s and Chadevarian et al.’s results [30, 31]. They re-
ported that increasing fibrinogen level was associated 
with rising levels of T4 and fT4. However, Yango et al. 
demonstrated that recombinant human TSH adminis-
tration had no effect on haemostatic parameters [32].
Plasma D-dimers level was also investigated in 
these three groups. It was higher before treatment, 
and then decreased in the hyperthyroidism group. 
After dividing into groups, results missed statistical 
significance, what may suggest that severity of thyroid 
disease is only one of the possible factors contributing 
to the coagulation-fibrinolytic balance. Our results 
contradict the findings of Chadevarian et al. [30]. They 
studied the fibrinolytic system in hypothyroid pa-
tients, and obtained different results according to the 
severity of hypothyroidism: higher levels of D-dimer 
in overt hypothyroidism and lower levels of D-dimer 
in moderate hypothyroidism. This issue has not been 
extensively investigated yet.
In subjects with overt hyperthyroidism, TSH and fT4 
correlated with plasma D-dimers level before treatment. 
There was positive correlation for fT4 and negative for 
TSH. D-dimers level did not depend on fT3. These re-
sults are inconsistent with previous observations. Cha-
darevian et al. observed a negative correlation between 
D-dimers and fT4, but they investigated patients with 
hyperlipidaemia who did not present symptoms of 
Table II. Correlation between D-dimers and anti-TPO in overt hyperthyroidism
Tabela II. Korelacja pomiędzy D-dimerami a anty-TPO w jawnej klinicznie nadczynności tarczycy
TPO antibodies 1 TPO antibodies 2 TPO antibodies 3
D–DIMERS 1 r = –0.24, p < 0.05 No calculation No calculation
D-DIMERS 2 r = –0.18, p < 0.01 r = 0.08, p < 0.001 No calculation














Fibrinogen and D-dimers levels in patients with hyperthyroidism Anna Brona et al.
thyroid disease [33]. Horne et al. found no changes in 
D-dimers level in thyroid cancer patients on thyroid 
hormone suppression therapy when they were hy-
pothyroid and hyperthyroid [22].This discrepancy may 
result from heterogeneity of the investigated groups 
— the presented studies did not concern D-dimers and 
fT4 in endogenous hyperthyroidism.
Both abnormal thyroid function and autoimmunity 
may modify haemostasis [1, 17]. Some concomitant 
autoimmune disorders involving the coagulation 
system have been described in thyroid dysfunction 
of autoimmune pathogenesis [3]. Panzer et al. investi-
gated patients with hyperthyroidism and low platelet 
count [6]. They found platelet-associated antibodies 
in three out of 15 subjects and suggested that platelet 
abnormalities are due to metabolic rather than immu-
nological processes. Petri et al. studied the prevalence 
of antiphospholipid antibodies in autoimmune thyroid 
disorders and in healthy individuals [34]. They found 
the same incidence of these antibodies in both groups. In 
another study, Marongiu et al. described a factor VIII 
inhibitor in Graves’ disease [35]. The same result was 
obtained by Sievert et al. [36]. They confirmed an as-
sociation between autoimmune thyroid disease and 
other autoimmune disorders. However, Porter et al. 
suggested that the presence of these antibodies may be 
the nonspecific mediator of immune system activation 
[12]. Contradictory results were presented by Cordiano 
et al. [37]. They reported that in 15 out of 18 patients with 
hyperthyroidism (Hashimoto’s thyroiditis and Graves’ 
disease) and thrombocytopenia, platelet autoantibodies 
were found. Hofbauer et al. and Suigmoto et al. revealed 
that restoring euthyroidism by antithyroid drug therapy 
caused remission of coagulation disorder [38, 39].
Marongiu et al. confirmed that antiphospholipid 
antibodies were more common in Graves’ disease pa-
tients than healthy controls [29]. Another possible 
mechanism for thrombocytopenia in patients with 
hyperthyroidism is binding of antibodies (other than 
TSH receptor antibodies) to proteins located on the 
thrombocyte membrane [8].The literature data shows 
an association between autoimmune thyroid diseases 
and autoimmune coagulation disturbances, although 
they are more likely to be concomitant disorders rather 
than caused by autoimmune thyroid disease [3].
However, Erem reported that an excess or a defi-
ciency of thyroid hormones affects the coagulation-fi-
brinolysis balance [1]. Squizatto et al. suggested that au-
toimmune mechanisms rarely contribute to this balance 
[5]. Shih et al. explained the role of thyroid hormone 
in the synthesis of blood clotting factors [19].They exert 
their effect through nuclear thyroid hormone receptors 
in hepatocytes. Erem et al. suggested that the coagula-
tion and fibrinolysis processes in hyperthyroidism are 
regardless of the aetiology [13]. They observed the same 
changes in haemostasis despite different pathogenesis 
of thyroid disease.
In order to determine the role of thyroid autoim-
munity in processes of haemostasis, we evaluated 
the association between fibrinogen, D-dimers and 
anti-TPO as indicators of underlying autoimmune 
processes. In a previous study Dörr et al. proposed 
that autoimmune thyroid disease might be responsi-
ble for an elevated level of inflammatory plasma pro-
teins [24]. Erem et al. supplemented the hypothesis 
that autoimmune processes modify haemostasis [1]. 
Some reports denied such an association, i.e. Squiz-
zato et al. postulated that the hypercoagulable state 
does not depend on the underlying pathophysiology 
of thyroid disease [5].
In subjects with hyperthyroidism, we observed 
a negative correlation between TPO antibodies level 
before treatment and plasma fibrinogen level meas-
ured at the same time. Similar correlation was found 
in subclinical and overt hyperthyroidism groups. In 
addition, the positive correlation between plasma 
fibrinogen level and TPO antibodies measured the sec-
ond time after treatment in the overt hyperthyroidism 
group suggests that the influence of autoimmunity on 
the coagulation-fibrinolytic system may be modified 
by other factors such as mode of treatment or sever-
ity of disease. Such a relation has not been discussed 
previously.
When D-dimers were considered in subjects with 
hyperthyroidism, a negative correlation was found 
between plasma D-dimers level measured the second 
time after radioiodine therapy and TPO antibodies 
measured before treatment. In subclinical and overt 
hyperthyroidism, a negative correlation was observed 
for measurements before and after treatment in dif-
ferent combinations. In contrast, no correlation was 
observed for the first measurement after treatment 
in the overt hyperthyroidism group, which may also 
support the hypothesis that other factors also exert 
an effect on haemostasis. There is no data available 
to compare with these results. However, the number 
of patients with autoimmune hyperthyroidism was 
very small.
Despite statistically important differences between 
fibrinogen and D-dimer level in patients with hyper-
thyroidism before and after treatment, the clinical 
importance of these changes is still being discussed.
Abnormalities of haemostasis range from subclinical 
laboratory findings to clinically significant disorders 
of haemostasis and, rarely, major thromboembolism 
[1, 3]. They are usually of limited consequence in clini-
cal practice [2]. However, major emboli may account 
for 18% of deaths associated with thyrotoxicosis and 
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the incidence of arterial thromboembolism is approxi-
mately 8–40% [11, 13]. The risk for thrombosis due to 
hypercoagulability increases in clinical hyperthyroidism 
[1, 23]. In our study, none of the patients presented with 
symptoms of thrombotic complications.
Conclusion
Hyperthyroidism exerts an effect on the coagulation-fi-
brinolytic balance. It affects plasma fibrinogen and 
D-dimers level. We found fibrinogen in the upper refer-
ence range and elevated D-dimers that decreased after 
treatment. This association depends on autoimmunity 
and severity of thyroid disease — the strongest relation-
ship is observed in overt hyperthyroidism. However, 
the number of cases was small, especially after dividing 
into subgroups. Thus, further studies are needed for 
a better understanding of these relations and for their 
quantitative ratio.
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